Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label dose-escalation study of PACAB-002 in ovarian cancer with peritoneal spread
NL-OMON61736Phase 1Not yet recruiting
- Sponsor
- NaDeNo Nanoscience
- Start
- Jan 2027
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PACAB-002 in ovarian cancer, sponsored by NaDeNo Nanoscience. Primary endpoint: Primary endpoint(s). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
PACAB-002
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON61736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61736.